Global vaccination at 10x accessability.

At Ensilica, we're eliminating the cold chain and and delivery costs of vaccines, which account for 90% of the total price.

Problem

Pneumonia vaccines are still not completely accessible

90% of the total cost of PCV-13 (targeted pneumonia vaccine) goes towards cold chain delivery and administration. The manufacturing of the vaccine is only $10, but it retails at $220.

Image representing Cas14 and CasPhi cutting DNA as part of the genome editing process
  • Environmental factors

    Environmental factors such as undernutrition, air pollution, overcrowding, among other external factors create breeding grounds for bacteria and air particles. These stimuli can damage your lungs and can weaken your immune system making people highly prone to Pneumonia.

  • Vaccine Cost

    Vaccines are too expensive for some families to afford, with a price of months of work for 5 children.

  • Vaccine storage

    The current pneumonia vaccine is to be stored at 2-8 degrees celcius. Because of improper storage, 50% of the vaccines are thrown out, and many don't get to the rural areas.

Ensilication

Reducing vaccine delivery costs (50% of total cost)

Proteins denature (unfold) in room temperatures. We use silica nanoparticle protection around proteins to physically prevent them from unfolding. The outcome of this process, a powder, can be stored at room temperature for 3 years.

Oral vaccination

Lung vaccination through the oral pathway

Following ensilication, the proteins (now in powder form) are compressed into a pill, which then travels to the stomach and releases the proteins at a specific ph level.

Image representing Cas14 and CasPhi cutting DNA as part of the genome editing process

The Vision

Hi, we’re Ensilica

We want to create a future where all children have access to life-saving vaccines, that kill 3 million people anually.

Our team

Ensilica was created by two 16 year olds who want to prevent child mortality around the world. We want to make sure that everyone has access to vaccinnes, and developed the Ensilica solution to achieve that.